Growing International Presence Kamada operates in over 30 countries with a portfolio of FDA-approved specialty plasma-derived products, indicating significant international sales potential and opportunities to expand distribution channels in emerging markets and regions with unmet medical needs.

FDA-Approved Infrastructure The recent FDA approval of Kamada's plasma collection center in San Antonio enhances its production capacity within the US, opening avenues for increased local sales, faster supply chain delivery, and strategic partnerships with healthcare providers.

Financial Growth and Stability With record-breaking revenues and a clear profit outlook in 2025, coupled with a consistent dividend policy, the company is positioned as a financially stable partner, making it attractive for sales of additional ancillary products or services in the biopharmaceutical supply chain.

Specialized Market Focus Kamada’s leadership in treating rare and serious conditions creates opportunities to target niche healthcare providers, hospitals, and clinics focusing on orphan diseases, enabling tailored sales approaches that address specific unmet medical needs.

Pipeline and Innovation Kamada’s progress in developing an innovative pipeline for unmet medical areas offers potential for future sales opportunities in new therapeutic segments, providing prospects for early partnership initiatives and co-marketing collaborations in novel biologics.